Federal Regulatory
DEA Emergency Schedules Bromazolam
March 18, 2026
The Drug Enforcement Administration (DEA) has placed bromazolam, a synthetic benzodiazepine with high abuse potential and no accepted medical use, into Schedule I of the Controlled Substances Act under an emergency scheduling order. This regulatory action imposes stringent controls on the manufacture, distribution, and possession of bromazolam to address its trafficking and abuse, particularly in counterfeit Xanax tablets. Procurement professionals involved in controlled substances, pharmaceutical manufacturing, and law enforcement supply chains should be aware of the new compliance requirements and restrictions effective immediately.
- Why this matters: Agencies and contractors handling controlled substances must update compliance protocols to reflect bromazolam's Schedule I status.
- This scheduling may impact procurement of raw materials, manufacturing processes, and distribution logistics related to benzodiazepines.
- Organizations involved in drug enforcement and diversion control should consider enhanced monitoring and reporting measures.
- Companies supplying pharmaceuticals or chemical precursors should evaluate contract terms and regulatory obligations to avoid sanctions.
The emergency scheduling of bromazolam is a decisive step to get ahead of a rapidly evolving threat. We will not wait for more lives to be put at risk.
— Cheri Oz
Agencies
Drug Enforcement Administration
Locations
Sources
- DEA Emergency Schedules Bromazolam · DEA · Mar 18